Global Access Growth Tanner Pharma’s 25+ years of experience across 150+ countries and focus on global patient access programs and clinical trial logistics indicate opportunities to upsell expanded access services, clinical trial supply optimization, and regional pilot programs for new partners expanding into international markets.

Strategic Partnerships Recent collaborations with Agenus and ongoing early access initiatives suggest a strong appetite for partner-driven access programs. This points to sales potential in multi-company alliances, co-developed access solutions, and joint programs for immuno-oncology and rare diseases.

Cold Chain Capabilities Expansion of -80°C freezer storage capabilities demonstrates capability to handle temperature-sensitive therapies. This creates cross-sell opportunities with manufacturers needing advanced cold-chain logistics for biologics, mRNA therapies, and precision medicines.

Access Programs Portfolio Success with innovative named patient programs and early access initiatives shows demand for flexible patient access models. There is potential to propose end-to-end access program design, regulatory navigation, and global distribution for additional therapeutic areas.

Industry Recognition Being named a Best Places to Work enhances talent and partner confidence, enabling outreach to larger biopharma and biotech organizations seeking reliable access partners with proven patient reach and compliant global distribution networks.